Yüksel Ürün, Prof. Dr. Ankara University School of Medicine, Department of Medical Oncology, shared a post on X:
“DESTINY-Breast09 shows: Enhertu + Pertuzumab > THP
Significant PFS benefit.
Consistent across all subgroups.
Early OS trend favoring combo.
Is this anew era in 1st-line HER2+ met. Breast cancer?”
